iaamexico.com

Research and Markets: Key Development Features of the Chinese Pharma Outsourcing Industry in 2009 and Its Development Outlook in 2010

Business Wire, Nov 23, 2009

DUBLIN — Research and Markets (http://www.researchandmarkets.com/research/21c0f7/china_pharma_outso)
has announced the addition of the “China
Pharma Outsourcing Annual Review 2009″ report to their offering.

It has been well recognized that 2009 is a rough year to all types of
industries worldwide. The financial crisis has significantly altered
both pharmaceutical and biotechnology industries on global scale. The
pharma outsourcing industry, both globally and in China, has also been
significantly affected. The Chinese pharma outsourcing industry suffered
a significant setback in 2009 if compared with the growth path of all
its previous years.

However, even though a significant decrease in outsourcing demand was
seen in almost every service sector of the Chinese pharma outsourcing
industry, its growth rate in 2009 is still so significant that could
make many of its rivals envy. In addition to the numerous advantages
China still possesses in pharma outsourcing, a number of new factors
also contributed to the further growth of the Chinese industry in 2009.

Encouraged by a large number of organizations and professionals that are
interested in this Chinese industry and that are eagerly seeking clues
of how the Chinese industry has been doing under the shadow of the
global financial crisis and how it will likely move in 2010, in this
Annual Review, we present the latest update of our research results on
this Chinese industry.

The Review starts with our in-depth analysis of how the global pharma
and biotech industries have been affected by the crisis and the impacts
of these changes on the global pharma outsourcing. It is then followed
by our detailed analysis of how the Chinese pharma outsourcing industry
has weathered the storm in the last twelve months or so.

The Review also well summarized all major events happened in 2009
including the outsourcing activities in China by drug companies from all
over the world, both major pharma and R&D-focused; biotech companies.

Also presented in the Review are the outlooks, based on our in-depth
analysis and study, of how the global pharma outsourcing in general and
the Chinese pharma outsourcing in specific will likely move in 2010.

The most distinct feature of the Review is the inclusion of the current
top ten professional pharma outsourcing service providers in the Chinese
pharma outsourcing industry, including the detailed description and
company profile of each player. To the best of our knowledge, this is
the first time that the top ten players of the Chinese pharma
outsourcing industry are successfully identified.

The Review will help readers not only gain a clear and deep insight into
what has happened to the Chinese pharma outsourcing industry in the past
year but also better understand how it will likely move next year. It is
a must-read book to all organizations and professionals in the
industries of pharmaceutical, biotechnology, outsourcing service and
financial investment that are interested in pharmaceutical outsourcing
in China.

Key Development Features of Chinese Pharma Outsourcing Industry in 2009
and Its Development Outlook in 2010

• The financial crisis has directly resulted in the significant
  reduction in R&D; spending industry-wide. It in turn resulted in the
  drastic decrease in the outsourcing demands. However, a more
  significant decrease occurred in the R&D-focused; biotech industry;
  whereas the outsourcing demands by the major pharma companies did not
  decrease significantly.
• In fact, what has been changed in the outsourcing demands by those
  major pharma companies is their research focus. As they now have more
  drug products in late development stages, their outsourcing focuses
  have been on further developing them. As a result, the outsourcing
  demands by the major companies for lead discovery and/or early stage
  development services have become significantly decreased.
• Before the beginning of 2009, we analyzed the possible impacts of the
  financial crisis on the Chinese pharma outsourcing industry including
  each service sector and made predictions of how this Chinese industry
  would likely develop in 2009. Now after one year since the arrival of
  the crisis, it has turned out that the market development of this
  Chinese industry, including all its service sectors, has been well in
  line with our predictions.
• Although still having performed relatively well compared to many of
  its counterparts in the world, overall, the Chinese pharma outsourcing
  industry did experience a significant growth slowdown in 2009.
• The most affected sectors are the drug discovery and contract
  manufacturing, each having a growth rate of only about 10-12% in 2009
  jon muranko